

Rafael Esteban

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/134216/publications.pdf>

Version: 2024-02-01

219
papers

13,638
citations

31902

53
h-index

24179

110
g-index

230
all docs

230
docs citations

230
times ranked

10034
citing authors

#	ARTICLE	IF	CITATIONS
1	Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 364, 1207-1217.	13.9	1,538
2	Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. <i>New England Journal of Medicine</i> , 2014, 370, 1993-2001.	13.9	752
3	Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 139, 120-129.e18.	0.6	633
4	Thrombocytopenia associated with chronic liver disease. <i>Journal of Hepatology</i> , 2008, 48, 1000-1007.	1.8	463
5	Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. <i>Journal of Hepatology</i> , 2004, 41, 38-43.	1.8	409
6	Evaluation of Antibodies to Hepatitis C Virus in a Study of Transfusion-Associated Hepatitis. <i>New England Journal of Medicine</i> , 1990, 323, 1107-1112.	13.9	397
7	Transmission of Hepatitis C Virus by a Cardiac Surgeon. <i>New England Journal of Medicine</i> , 1996, 334, 555-561.	13.9	360
8	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.	1.8	358
9	Paracentesis with Intravenous Infusion of Albumin as Compared with Peritoneovenous Shunting in Cirrhosis with Refractory Ascites. <i>New England Journal of Medicine</i> , 1991, 325, 829-835.	13.9	294
10	Cardiac alterations in cirrhosis: reversibility after liver transplantation. <i>Journal of Hepatology</i> , 2005, 42, 68-74.	1.8	281
11	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	3.6	239
12	The development of low-grade cerebral edema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. <i>Journal of Hepatology</i> , 2001, 35, 598-604.	1.8	233
13	High-Throughput Real-Time Reverse Transcription-PCR Quantitation of Hepatitis C Virus RNA. <i>Journal of Clinical Microbiology</i> , 1999, 37, 327-332.	1.8	223
14	Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. <i>Hepatology</i> , 2001, 34, 404-410.	3.6	206
15	Quality of life and cognitive function in hepatitis C at different stages of liver disease. <i>Journal of Hepatology</i> , 2003, 39, 231-238.	1.8	196
16	Hepatitis B virus infection: Precore mutants and its relation to viral genotypes and core mutations. <i>Hepatology</i> , 1995, 22, 1641-1647.	3.6	184
17	Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. <i>Journal of Hepatology</i> , 2010, 52, 658-664.	1.8	155
18	Effects of Branched-Chain Amino Acids Supplementation in Patients With Cirrhosis and a Previous Episode of Hepatic Encephalopathy: A Randomized Study. <i>American Journal of Gastroenterology</i> , 2011, 106, 1081-1088.	0.2	151

#	ARTICLE	IF	CITATIONS
19	Combined treatment with pegylated interferon ($\hat{1}\pm$ -2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2005, 43, 53-59.	1.8	148
20	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015, 62, 363-370.	1.8	138
21	Predicting Early Mortality After Acute Variceal Hemorrhage Based on Classification and Regression Tree Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1347-1354.	2.4	137
22	Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: A prospective study. <i>Journal of Hepatology</i> , 2014, 60, 561-569.	1.8	124
23	Quality of life in cirrhosis is related to potentially treatable factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 221-227.	0.8	121
24	Long-Term Immunogenicity and Efficacy of Hepatitis B Vaccine in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 1992, 12, 144-147.	1.4	117
25	Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel. <i>Journal of Hepatology</i> , 2011, 54, 1250-1262.	1.8	110
26	Effectiveness of Combined Pharmacologic and Ligation Therapy in High-Risk Patients With Acute Esophageal Variceal Bleeding. <i>American Journal of Gastroenterology</i> , 2011, 106, 1787-1795.	0.2	108
27	Interferon- $\hat{1}\pm$ in acute posttransfusion hepatitis C: A randomized, controlled trial. <i>Hepatology</i> , 1992, 15, 767-769.	3.6	107
28	Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. <i>Hepatology</i> , 2002, 35, 930-936.	3.6	106
29	Interleukin-6, Nitric Oxide, and the Clinical and Hemodynamic Alterations of Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 1999, 94, 169-177.	0.2	103
30	Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 42, 639-645.	1.8	103
31	Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study. <i>Journal of Hepatology</i> , 2013, 59, 1184-1192.	1.8	102
32	Adherence to Lamivudine After an Early Withdrawal of Hepatitis B Immune Globulin Plays an Important Role in the Long-Term Prevention of Hepatitis B Virus Recurrence. <i>Transplantation</i> , 2007, 84, 650-654.	0.5	94
33	Sporadic cases of acute autochthonous hepatitis E in Spain. <i>Journal of Hepatology</i> , 2004, 41, 126-131.	1.8	93
34	Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2005, 42, 173-179.	1.8	92
35	Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. <i>Liver Transplantation</i> , 2006, 12, 95-104.	1.3	89
36	Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. <i>Journal of Hepatology</i> , 2014, 61, 228-234.	1.8	88

#	ARTICLE	IF	CITATIONS
37	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	1.8	88
38	Neuropsychological abnormalities in cirrhosis include learning impairment. <i>Journal of Hepatology</i> , 2006, 44, 104-110.	1.8	78
39	Community-Based Seroepidemiological Survey of Hepatitis E Virus Infection in Catalonia, Spain. <i>Vaccine Journal</i> , 2006, 13, 1328-1332.	3.2	77
40	Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2009, 51, 640-646.	1.8	76
41	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	1.8	75
42	Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. <i>Hepatology</i> , 2001, 34, 1035-1040.	3.6	74
43	High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. <i>Journal of Clinical Microbiology</i> , 2015, 53, 219-226.	1.8	74
44	Management of direct-acting antiviral agent failures. <i>Journal of Hepatology</i> , 2015, 63, 1511-1522.	1.8	73
45	Nucleotide and Amino Acid Complexity of Hepatitis C Virus Quasispecies in Serum and Liver. <i>Journal of Virology</i> , 2000, 74, 805-811.	1.5	71
46	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	1.8	69
47	Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. <i>Virology</i> , 2008, 370, 237-245.	1.1	67
48	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019, 71, 666-672.	1.8	67
49	Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?. <i>Journal of Hepatology</i> , 2002, 36, 445-446.	1.8	64
50	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. <i>Hepatology</i> , 2010, 52, 1201-1207.	3.6	63
51	Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2000, 33, 651-658.	1.8	63
52	Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases. <i>Hepatology</i> , 2003, 37, 1226-1227.	3.6	58
53	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 784-793.	1.1	55
54	Hemodynamic response-guided therapy for prevention of variceal rebleeding: An uncontrolled pilot study. <i>Hepatology</i> , 2006, 44, 806-812.	3.6	54

#	ARTICLE	IF	CITATIONS
55	A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. <i>Antiviral Research</i> , 2013, 98, 273-283.	1.9	53
56	Long interval between HCV infection and development of hepatocellular carcinoma. <i>Liver</i> , 1995, 15, 159-163.	0.1	52
57	Efficacy and safety of boceprevir plus peginterferon+ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 479-487.	1.8	52
58	Serological diagnosis of acute delta hepatitis. <i>Journal of Medical Virology</i> , 1986, 18, 81-85.	2.5	49
59	Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. <i>Journal of Clinical Virology</i> , 2005, 34, S79-S82.	1.6	49
60	Ultra-Deep Pyrosequencing Detects Conserved Genomic Sites and Quantifies Linkage of Drug-Resistant Amino Acid Changes in the Hepatitis B Virus Genome. <i>PLoS ONE</i> , 2012, 7, e37874.	1.1	49
61	Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 158-166.	1.9	49
62	Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. <i>Journal of Hepatology</i> , 2004, 40, 507-514.	1.8	47
63	Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. <i>Hepatology</i> , 2012, 56, 567-575.	3.6	47
64	Cirrhosis, Liver Transplantation and HIV Infection Are Risk Factors Associated with Hepatitis E Virus Infection. <i>PLoS ONE</i> , 2014, 9, e103028.	1.1	46
65	Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 619-629.	1.4	45
66	Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. <i>PLoS ONE</i> , 2017, 12, e0184550.	1.1	45
67	Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. <i>Journal of Virological Methods</i> , 1999, 83, 181-187.	1.0	44
68	Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA. <i>Hepatology</i> , 2004, 40, 133-139.	3.6	44
69	Hemoperitoneum as a first manifestation of hepatocellular carcinoma in western patients with liver cirrhosis: effectiveness of emergency treatment with transcatheter arterial embolization. <i>Digestive Diseases and Sciences</i> , 2001, 46, 555-562.	1.1	43
70	Hepatitis D virus RNA in acute delta infection: Serological profile and correlation with other markers of hepatitis D virus infection. <i>Hepatology</i> , 1988, 8, 1125-1129.	3.6	42
71	The value of quantitative detection of HBV-DNA amplified by PCR in the study of hepatitis B infection. <i>Journal of Hepatology</i> , 1996, 24, 680-685.	1.8	42
72	Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. <i>Liver International</i> , 1999, 19, 177-182.	1.9	42

#	ARTICLE	IF	CITATIONS
73	Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. <i>Nucleic Acids Research</i> , 2011, 39, 8457-8471.	6.5	42
74	Superiority of Interferon-Free Regimens for Chronic Hepatitis C. <i>Medicine (United States)</i> , 2017, 96, e5914.	0.4	42
75	Epidemiology of hepatitis C virus infection. <i>Journal of Hepatology</i> , 1993, 17, S67-S71.	1.8	41
76	Hepatitis E virus infection in acute hepatitis in Spain. <i>Journal of Virological Methods</i> , 1995, 55, 49-54.	1.0	40
77	Specific Cleavage of Hepatitis C Virus RNA Genome by Human RNase P. <i>Journal of Biological Chemistry</i> , 2002, 277, 30606-30613.	1.6	40
78	Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2000, 33, 651-658.	1.8	39
79	Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2012, 56, 313-319.	1.8	39
80	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
81	Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. <i>Liver International</i> , 2018, 38, 84-89.	1.9	38
82	Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts. <i>Journal of Hepatology</i> , 2004, 40, 552-557.	1.8	37
83	Chronic delta hepatitis: Detection of hepatitis delta virus antigen in serum by immunoblot and correlation with other markers of delta viral replication. <i>Hepatology</i> , 1989, 10, 907-910.	3.6	36
84	Hepatitis B vaccination in liver transplant candidates. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 359-361.	0.8	36
85	Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. <i>Journal of Hepatology</i> , 1998, 28, 510-513.	1.8	35
86	Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. <i>Journal of Hepatology</i> , 2008, 49, 695-701.	1.8	35
87	Prevalence of Hepatitis E Virus Infection in Children in the Northeast of Spain. <i>Vaccine Journal</i> , 2008, 15, 732-734.	3.2	35
88	Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. <i>Journal of Hepatology</i> , 2009, 51, 1091-1096.	1.8	34
89	Management of direct antiviral agent failures. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 432-438.	4.5	34
90	Treatment with Interferon plus Ribavirin in anti-HIV Negative Patients with Congenital Coagulation Disorders and Chronic Hepatitis C. <i>Thrombosis and Haemostasis</i> , 2000, 83, 807-810.	1.8	33

#	ARTICLE	IF	CITATIONS
91	Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. <i>Liver Transplantation</i> , 2002, 8, 892-900.	1.3	33
92	Effect of Bottlenecking on Evolution of the Nonstructural Protein 3 Gene of Hepatitis C Virus during Sexually Transmitted Acute Resolving Infection. <i>Journal of Virology</i> , 2005, 79, 15131-15141.	1.5	31
93	Liver Transplantation in HIV-HCV Coinfected Patients: A Case-Control Study. <i>Transplantation</i> , 2007, 83, 354-358.	0.5	31
94	Development of sofosbuvir for the treatment of hepatitis C virus infection. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 56-67.	1.8	31
95	Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication. <i>Journal of Hepatology</i> , 1995, 22, 272-277.	1.8	30
96	Chronic delta hepatitis: Is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections?. , 1996, 49, 66-69.		30
97	Are recipients of solid organ transplantation a high-risk population for hepatitis E virus infection?. <i>Liver Transplantation</i> , 2010, 16, 106-107.	1.3	30
98	Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. <i>Hepatology</i> , 2012, 56, 706-714.	3.6	30
99	Hepatitis delta genotypes in chronic delta infection in the northeast of Spain (Catalonia). <i>Journal of Hepatology</i> , 1998, 28, 971-977.	1.8	29
100	Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. <i>BMC Infectious Diseases</i> , 2018, 18, 446.	1.3	29
101	Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. <i>Journal of Hepatology</i> , 2008, 49, 43-51.	1.8	28
102	Longitudinal Evaluation of the Structure of Replicating and Circulating Hepatitis C Virus Quasispecies in Nonprogressive Chronic Hepatitis C Patients. <i>Journal of Virology</i> , 2001, 75, 12005-12013.	1.5	27
103	Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. <i>Aids</i> , 2007, 21, 477-481.	1.0	27
104	Quantitative Hepatitis B Virus DNA Testing for the Early Prediction of the Maintenance of Response during Lamivudine Therapy in Patients with Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2001, 183, 1277-1280.	1.9	26
105	Clinical Application of Estimating Hepatitis B Virus Quasispecies Complexity by Massive Sequencing: Correlation between Natural Evolution and On-Treatment Evolution. <i>PLoS ONE</i> , 2014, 9, e112306.	1.1	26
106	Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials. <i>Journal of Hepatology</i> , 2014, 61, 200-209.	1.8	26
107	Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?. <i>Journal of Viral Hepatitis</i> , 2020, 27, 747-753.	1.0	26
108	One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 462-469.	1.9	25

#	ARTICLE	IF	CITATIONS
109	Etiology of acute sporadic hepatitis in Spain: the role of hepatitis C and E viruses. <i>Journal of Hepatology</i> , 1994, 20, 589-592.	1.8	24
110	Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon α -2b plus ribavirin. <i>Journal of Hepatology</i> , 2004, 40, 527-532.	1.8	24
111	Triple therapy for <sc>HCV</sc> genotype 1 infection: telaprevir or boceprevir?. <i>Liver International</i> , 2012, 32, 54-60.	1.9	24
112	Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial. <i>Hepatology</i> , 1995, 22, 439-445.	3.6	23
113	Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 320-326.	0.8	23
114	Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. <i>Liver International</i> , 2010, 30, 593-602.	1.9	23
115	High doses of β -blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. <i>Liver International</i> , 2010, 30, 1123-1130.	1.9	23
116	Early Antiviral Treatment of Hepatitis C Virus Recurrence after Liver Transplantation in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2006, 11, 1061-1070.	0.6	23
117	Response-Guided Therapy for Chronic Hepatitis C Virus Infection in Patients Coinfected with HIV: A Pilot Trial. <i>Clinical Infectious Diseases</i> , 2009, 48, 1152-1159.	2.9	22
118	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study. <i>Antiviral Research</i> , 2011, 92, 90-95.	1.9	22
119	New therapeutic perspectives in <sc>HBV</sc>: when to stop <sc>NA</sc>s. <i>Liver International</i> , 2014, 34, 146-153.	1.9	22
120	Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 805-813.	3.7	22
121	Healthcare value of implementing hepatitis C screening in the adult general population in Spain. <i>PLoS ONE</i> , 2018, 13, e0208036.	1.1	22
122	Determination of hepatitis delta virus RNA by polymerase chain reaction in acute and chronic delta infection. <i>Hepatology</i> , 1995, 21, 25-29.	3.6	21
123	Drugs in Development for Hepatitis B. <i>Drugs</i> , 2005, 65, 1451-1460.	4.9	21
124	Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection. <i>Journal of Infectious Diseases</i> , 2017, 216, S792-S796.	1.9	21
125	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. <i>Clinical Infectious Diseases</i> , 2018, 66, 1742-1750.	2.9	21
126	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <i>Gastroenterología Y Hepatología</i> (English Edition), 2020, 43, 559-587.	0.0	20

#	ARTICLE	IF	CITATIONS
127	Recurrent hepatitis C virus infection after liver transplantation: Immunohistochemical assessment of the viral antigen. <i>Liver Transplantation</i> , 1998, 4, 320-327.	1.9	19
128	Sexual Transmission of Hepatitis C Virus From a Patient With Chronic Disease to His Sex Partner After Removal of an Intrauterine Device. <i>Sexually Transmitted Diseases</i> , 2003, 30, 470-471.	0.8	19
129	Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?. <i>Annals of Hepatology</i> , 2011, 10, 180-187.	0.6	19
130	Evidence of an Exponential Decay Pattern of the Hepatitis Delta Virus Evolution Rate and Fluctuations in Quasispecies Complexity in Long-Term Studies of Chronic Delta Infection. <i>PLoS ONE</i> , 2016, 11, e0158557.	1.1	19
131	Financial Impact of Two Different Ways of Evaluating Early Virological Response to Peginterferon-??-2b Plus Ribavirin Therapy in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1. <i>Pharmacoeconomics</i> , 2005, 23, 1043-1055.	1.7	18
132	Documento de consenso de la Asociaci3n Espa±ola para el Estudio del HÃgado sobre el tratamiento de la infecci3n por el virus de la hepatitis B (2020). <i>GastroenterologÃa Y HepatologÃa</i> , 2020, 43, 559-587.	0.2	18
133	Hepatitis B virus and hepatitis D virus replication in HBsAg-positive fulminant hepatitis. <i>Hepatology</i> , 1990, 11, 1062-1065.	3.6	17
134	Clinical significance of two forms of IgM antibody to hepatitis delta virus. <i>Hepatology</i> , 1991, 14, 25-28.	3.6	17
135	Nosocomial transmission of hepatitis C virus during contrast-enhanced computed tomography scanning. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 73-78.	0.8	17
136	Relevance of a Full-Length Genomic RNA Standard and a Thermal-Shock Step for Optimal Hepatitis Delta Virus Quantification. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3334-3338.	1.8	17
137	Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy. <i>World Journal of Gastroenterology</i> , 2018, 24, 2095-2107.	1.4	17
138	Reflex viral load testing in dried blood spots generated by plasma separation card allows the screening and diagnosis of chronic viral hepatitis. <i>Journal of Virological Methods</i> , 2021, 289, 114039.	1.0	17
139	Prevalence of Hepatitis G Virus in Healthy Children in Liver Disease, and Human Immunodeficiency Virus-1 Infection: Response to Interferon. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2000, 30, 385-390.	0.9	17
140	Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment. <i>Journal of Hepatology</i> , 2000, 32, 843-849.	1.8	16
141	Structural analysis of hepatitis C RNA genome using DNA microarrays. <i>Nucleic Acids Research</i> , 2004, 32, e90-e90.	6.5	16
142	Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?. <i>Journal of Clinical Virology</i> , 2015, 68, 61-68.	1.6	15
143	Hepatitis C virus genotype 3: a genotype that is not "easy-to-treat"™. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 375-385.	1.4	15
144	Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. <i>Journal of Clinical Microbiology</i> , 2017, 55, 504-509.	1.8	15

#	ARTICLE	IF	CITATIONS
145	Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing. <i>World Journal of Gastroenterology</i> , 2012, 18, 6096.	1.4	15
146	Molecular epidemiology and putative origin of hepatitis C virus in random volunteers from Argentina. <i>World Journal of Gastroenterology</i> , 2013, 19, 5813.	1.4	15
147	Serological profile of tissue autoantibodies during acute and chronic delta hepatitis. <i>Journal of Hepatology</i> , 1989, 9, 345-350.	1.8	14
148	Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension. <i>Liver International</i> , 2012, 32, 1295-1305.	1.9	14
149	Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 445-453.	1.0	14
150	Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin. <i>Transfusion</i> , 2018, 58, 2501-2505.	0.8	14
151	HBV core region variability: effect of antiviral treatments on main epitopic regions. <i>Antiviral Therapy</i> , 2011, 16, 37-49.	0.6	14
152	Comparative analysis of serological markers of chronic delta infection: HDV-RNA, serum HDAg and anti-HD IgM. <i>Journal of Virological Methods</i> , 1994, 50, 59-66.	1.0	13
153	Role of Biomarkers in Guiding Cure of Viral Hepatitis B. <i>Seminars in Liver Disease</i> , 2020, 40, 049-060.	1.8	13
154	Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Liver International</i> , 2020, 40, 15-21.	1.9	13
155	Profiles and clinical management of hepatitis C patients in Spain: disHCover study. <i>Revista Espanola De Quimioterapia</i> , 2015, 28, 145-53.	0.5	13
156	Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients. <i>Journal of Hepatology</i> , 2006, 44, S60-S64.	1.8	12
157	Etiologies and Features of Acute Viral Hepatitis in Spain. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1030-1037.	2.4	12
158	Adefovir dipivoxil. <i>Drugs of Today</i> , 2003, 39, 127.	2.4	12
159	Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 2000, 45, 685-689.	1.1	11
160	Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. <i>Hepatology</i> , 2012, 56, 1849-1860.	3.6	11
161	Alcohol consumption and risk of infection after a variceal bleeding in low-risk patients. <i>Liver International</i> , 2016, 36, 994-1001.	1.9	11
162	Quantitative characterization of hepatitis delta virus genome edition by next-generation sequencing. <i>Virus Research</i> , 2018, 243, 52-59.	1.1	11

#	ARTICLE	IF	CITATIONS
163	Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612098595.	1.1	11
164	Adefovir for Chronic Hepatitis B Treatment: Identification of Virological Markers Linked to Therapy Response. <i>Antiviral Therapy</i> , 2008, 13, 991-999.	0.6	11
165	Usefulness of magnetic resonance spectroscopy for diagnosis of hepatic encephalopathy in a patient with relapsing confusional syndrome. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2451-2455.	1.1	10
166	De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. <i>International Urology and Nephrology</i> , 2008, 40, 539-541.	0.6	10
167	Identification of host and viral factors involved in a dissimilar resolution of a hepatitis C virus infection. <i>Liver International</i> , 2014, 34, 896-906.	1.9	10
168	Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population. <i>World Journal of Gastroenterology</i> , 2018, 24, 680-692.	1.4	10
169	Use of the Novel INNO-LiPA Line Probe Assay for Detection of Hepatitis B Virus Variants That Confer Resistance to Entecavir Therapy. <i>Journal of Clinical Microbiology</i> , 2009, 47, 485-488.	1.8	9
170	Current trends in chronic hepatitis B management: results of a questionnaire. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1177-1183.	0.8	9
171	Complex Genotype Mixtures Analyzed by Deep Sequencing in Two Different Regions of Hepatitis B Virus. <i>PLoS ONE</i> , 2015, 10, e0144816.	1.1	9
172	Treatment of chronic type D hepatitis and concomitant human immunodeficiency infection with α -interferon. <i>Journal of Hepatology</i> , 1992, 14, 412-413.	1.8	8
173	Spontaneous bacterial peritonitis caused by quinolone-resistant <i>Escherichia coli</i> : could steroid therapy play a role?. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 81-83.	0.8	8
174	1990–2010: Two Decades of Interferon-Based Therapy. <i>Clinics in Liver Disease</i> , 2011, 15, 473-482.	1.0	8
175	Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100280.	2.6	8
176	Inhibition of Neuronal Apoptosis and Axonal Regression Ameliorates Sympathetic Atrophy and Hemodynamic Alterations in Portal Hypertensive Rats. <i>PLoS ONE</i> , 2014, 9, e84374.	1.1	8
177	Conservation and variability of hepatitis B core at different chronic hepatitis stages. <i>World Journal of Gastroenterology</i> , 2020, 26, 2584-2598.	1.4	8
178	The presence of anti-hcv antibodies in the serum of patients with chronic active hepatitis and antinuclear antibodies. <i>Hepatology</i> , 1990, 11, 333-335.	3.6	7
179	Drug-Induced Lupus-Like Reaction and Captopril. <i>Annals of Pharmacotherapy</i> , 1993, 27, 1541-1542.	0.9	7
180	Detection of hepatitis B precore mutants by the fluorescent linear polymerase chain reaction sequencing method. <i>Journal of Hepatology</i> , 1994, 21, 934-939.	1.8	7

#	ARTICLE	IF	CITATIONS
181	Which is the Most Cost-Effective Combination Therapy Strategy Using Interferon α -2b plus Ribavirin for Naïve Patients with Chronic Hepatitis C?. <i>Clinical Drug Investigation</i> , 2002, 22, 31-39.	1.1	7
182	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. <i>Digestive and Liver Disease</i> , 2020, 52, 1164-1169.	0.4	7
183	Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection. <i>World Journal of Gastroenterology</i> , 2019, 25, 1566-1579.	1.4	7
184	Cost-effectiveness analysis of an active search to retrieve <sc>HCV</sc> patients lost to follow-up (<sc>RELINK</sc> strategy) and the impact of <sc>COVID</sc> 19. <i>Journal of Viral Hepatitis</i> , 2022, 29, 579-583.	1.0	7
185	Risk of hepatitis B in infancy and childhood. <i>Vaccine</i> , 1995, 13, S35-S36.	1.7	6
186	Infrequent detection of hepatitis E virus RNA in pregnant women with hepatitis E virus antibodies in Spain. <i>Liver International</i> , 2010, 30, 1549-1551.	1.9	6
187	Twelve-Week Posttreatment Follow-Up to Predict Sustained Virologic Response for Recurrent Hepatitis C Infection in Liver Recipients. <i>Transplantation</i> , 2012, 93, 450-453.	0.5	6
188	Adding banding ligation is effective as rescue therapy to prevent variceal rebleeding in haemodynamic non-responders to pharmacological therapy. <i>Digestive and Liver Disease</i> , 2012, 44, 55-60.	0.4	6
189	New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors. <i>Journal of General Virology</i> , 2018, 99, 97-102.	1.3	6
190	New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. <i>Infection and Drug Resistance</i> , 2010, 3, 133.	1.1	5
191	The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats. <i>Liver International</i> , 2015, 35, 326-334.	1.9	5
192	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	2.6	5
193	Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. <i>World Journal of Gastroenterology</i> , 2021, 27, 5112-5125.	1.4	5
194	Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. <i>Clinics in Liver Disease</i> , 2021, 25, 725-740.	1.0	5
195	New real-time-PCR method to identify single point mutations in hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2016, 22, 9604.	1.4	5
196	Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. <i>Antiviral Therapy</i> , 2008, 13, 991-9.	0.6	5
197	Improved Attachment of Natural HCV Isolate to Daudi Cells upon Elimination of Immune Complexes and Close pH Control. <i>Intervirology</i> , 2005, 48, 285-291.	1.2	4
198	Reply to: "The importance of prognostic factors in cirrhosis". <i>Journal of Hepatology</i> , 2014, 60, 1326.	1.8	4

#	ARTICLE	IF	CITATIONS
199	Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity. <i>Annals of Hepatology</i> , 2019, 18, 215-219.	0.6	4
200	Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide. <i>Liver International</i> , 2021, 41, 9-14.	1.9	4
201	Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 619-626.	0.1	4
202	Letters to the Editor. <i>Journal of Hepatology</i> , 2000, 32, 362-363.	1.8	3
203	Can interferon prolong life?. <i>Hepatology</i> , 2003, 38, 292-294.	3.6	3
204	Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues. <i>Journal of Medical Virology</i> , 2007, 79, 1671-1673.	2.5	3
205	Patient experience in HCV therapy: what really matters. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 90-92.	3.7	3
206	Interferon vs. adenine arabinoside 5â€²-monophosphate in patients with anti-HBe-positive chronic hepatitis. , 1996, 49, 325-328.		2
207	Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?. <i>Hepatology</i> , 2019, 69, 2701-2703.	3.6	2
208	Applicability of real-time PCR combined with melting curve analysis for the study of hepatitis B virus genome mutations. <i>Hepatology</i> , 2003, 37, 478-479.	3.6	1
209	Adefovir for lamivudine resistant HBV: More than meets the eye â€“ Reply. <i>Journal of Hepatology</i> , 2007, 47, 619-620.	1.8	1
210	Preparing the patient for success: Treat or wait?. <i>Digestive and Liver Disease</i> , 2013, 45, S332-S336.	0.4	1
211	Joan Cordoba Cordona (1964â€“2014): A dedicated clinician, great scientist, mentor, friend, collaborator, criticâ€¦. <i>Journal of Hepatology</i> , 2014, 60, 1105-1107.	1.8	1
212	Study of hepatitis B virus quasispecies by ultra-deep pyrosequencing: Resolving the nitty-gritty. <i>Hepatology</i> , 2014, 59, 1210-1212.	3.6	1
213	Therapy With Direct-Acting Antivirals for Genotype 3 Patients: Interferonâ€™s Last Gasp?. <i>Gastroenterology</i> , 2015, 149, 1326-1330.	0.6	1
214	Baseline HCVâ€™RNA levels in genotype 1 chronic hepatitis C patients: The role of different cutâ€™off points. <i>Hepatology</i> , 2016, 64, 1385-1386.	3.6	1
215	ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	1
216	Delta agent in nondrug addicts. <i>Hepatology</i> , 1985, 5, 526-528.	3.6	0

#	ARTICLE	IF	CITATIONS
217	Reply:. Hepatology, 2010, 52, 1520-1521.	3.6	0
218	Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients. Annals of Hepatology, 2014, 13, 219-230.	0.6	0
219	Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110165.	1.4	0